NCT07168291 - Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Diffuse Large B Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Burkitt Lymphoma

Interventions

DRUG

Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion

Cyclophosphamide 250 mg/m2 and fludarabine 30 mg/m2 IV infusion on day -5, -4, and -3. AbTCR (anti-CD19/CD22)-T cell IV infusion on day 0.

Trial Locations (1)

First Affiliated Hospital of Xi'an Jiaotong University, Xi'an